| Three organizations, the CDC, the American Thoracic Society
and The Infectious Diseases Society of America, have published separate
clinical practice guidelines for the treatment of community- acquired
pneumonia. These clinical practice guidelines provide evidence-based
recommendations for clinicians to optimize therapy. In December 2003,
the Infectious Diseases Society of America published an update of CAP.
The purpose of the update is to answer questions arising from evolving
antimicrobial resistance and advances in technology. The IDSA update
provides information in tabular format, |
|
along with text. IDSA guidelines update the criteria
for initial selection of site of therapy; initial empiric therapy;
changes in the MIC for extended spectrum cephalosporins; diagnostic
test updates; SARS; bioterrorism and prevention. Here are some areas
of change to note: For all inpatients, initial therapy should occur
after blood and sputum cultures are obtained and the first doses of
antibiotics should be administered within four hours of the decision
to admit. Initial therapy for most patients remains as a macrolide
with or with out a beta-lactam; or a respiratory fluoroquinolone |
|
(gatifloxacin, levofloxacin, moxifloxacin, or gemifloxacin). An extended
spectrum cephalosporin (cefotaxime or ceftriaxone) is still the recommended
agent for penicillin resistant streptococcus pneumonia. The MIC has
been revised for nonmeningococcal isolates of S. pneumonia. A MIC <=
1 mcg/ml is now considered sensitive, MIC = 2 mcg/ml is intermediate,
MIC > 4mcg/ml is resistant. The prior MIC breakpoints were reflective
of the need to maintain higher concentrations to cross into the CNS.
Pharmacists should consider the new MIC breakpoints when making recommendations. |